Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2025 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de service
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to The Report
Fundraising

10x Genomics

10x Genomics Raises $55M in Series E

2012
Founded
800+
Employees
Pleasanton, CA
Updated January 10, 2018
2 min read

Quick Facts

10x Genomics Raises $55M in Series E


10x Genomics has successfully raised $55M in a Series E at a $500M valuation led by Softbank Vision Fund, Fidelity.


Company Overview


10x Genomics is a Biotech company headquartered in Pleasanton, CA, founded in 2012 with 800+ employees.


Single-cell genomics and spatial biology


Fundraising Details


  • Amount Raised: $55M
  • Round Type: Series E
  • Valuation: $500M
  • Date: 2018-01-10
  • Investors: Softbank Vision Fund, Fidelity

About 10x Genomics


Single-cell genomics and spatial biology The company is positioned in the Biotech sector, serving a growing market with innovative solutions.


Key Information


  • Headquarters: Pleasanton, CA
  • Founded: 2012
  • Team Size: 800+
  • Industry: Biotech

What This Means


This funding round demonstrates strong investor confidence in 10x Genomics's vision and execution. The capital will likely be used to:


  • Scale Operations: Expand the team and operational capacity
  • Product Development: Enhance existing products and develop new features
  • Market Expansion: Enter new markets and strengthen presence in existing ones
  • Technology Investment: Invest in infrastructure and technology capabilities

Industry Context


The Biotech sector continues to attract significant investment as companies innovate to meet evolving market demands. 10x Genomics's successful fundraising reflects the strong fundamentals and growth potential in this space.


Valuation Milestone


Reaching a $500M valuation marks an important milestone for 10x Genomics, positioning the company among notable players in the Biotech industry.


Looking Ahead


With this new capital, 10x Genomics is well-positioned to execute on its growth strategy and continue building innovative solutions in the Biotech space. The company's trajectory will be one to watch as it deploys this funding to achieve its next phase of growth.


This fundraising news was reported on 2018-01-10. For more information about 10x Genomics, visit their headquarters at Pleasanton, CA.

Topics

Fundraising(2912)BiotechSeries E10x Genomics

About the Author

Fundraising News Team
Fundraising News Team
Tracking the latest funding rounds and investment news

Related Company Reports

Fundraising
Harvey AI

Harvey AI Raises $160 million in Series F

Harvey AI, a AI Software company based in San Francisco CA, has raised $160 million in Series F at a $8 billion valuation led by Andreessen Horowitz.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•160 million
Fundraising
7AI

7AI Raises $130 million in Series A

7AI, a Cybersecurity company based in Boston MA, has raised $130 million in Series A at a $700 million valuation led by Index Ventures.

Market Intelligence Team
Market Intelligence Team
Dec 4, 2025
0 min read•130 million
Fundraising
TRIANA Biomedicines

TRIANA Biomedicines Raises $120 million in Series B

TRIANA Biomedicines, a Biotechnology company based in Lexington MA, has raised $120 million in Series B at a Undisclosed led by Ascenta Capital.

Market Intelligence Team
Market Intelligence Team
Dec 3, 2025
0 min read•120 million